A.D.A.M. and the Icahn School of Medicine at Mount Sinai Announce Collaboration to Advance Bone Implant Technology and Healthcare Innovation

Collaboration

Advanced Development of Additive Manufacturing (A.D.A.M.), a provider of 3D printing systems for customized bone implants, and the Icahn School of Medicine at Mount Sinai, in New York, NY, a renowned educational and health institution, have established a collaboration, which aims to enhance healthcare by innovating in bone implant delivery and soft tissue medical device development.

Agreement

The agreement involves A.D.A.M. and Mount Sinai BioDesign, Icahn Mount Sinai’s medical device innovation incubator, combining their technological and expert capabilities to improve patient care in the field of bone implant delivery.

Denys Gurak, CEO and Founder of A.D.A.M.

“Our collaboration with Icahn Mount Sinai leverages our advanced medical device production system and Icahn Mount Sinai’s expertise to improve patient care in healthcare.”

Benjamin Rapoport, MD, PhD, Assistant Professor of Neurosurgery and Scientific Director of Mount Sinai BioDesign

“Our collaboration with A.D.A.M. unites our medical device innovation skills with their 3D printing technology, reflecting our dedication to solving healthcare challenges through joint efforts.”

The collaboration will conduct research and development in 3D printed bone tissues using A.D.A.M.’s technology and will explore soft tissue printing through the new “Soft Tissues Working Group.”

An important aspect of this relationship will be work conducted at A.D.A.M. ‘s pilot facility at the Masovian Regional Hospital in Siedlce, Poland.

A.D.A.M. Inc. was a participant of the 2022 Spring Cohort of Mount Sinai Innovation Partners’ Elementa Labs incubator program and Icahn Mount Sinai has a financial interest in the company.

SourceA.D.A.M.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Tabrecta is the first FDA-approved therapy to treat non small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study.
Thirona notes LungQ 3.0.0 builds on 10 years of clinical trials and 200+ publications to deliver advanced segmentation of pulmonary segments and subsegments.
The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with "GPS-like" guidance with millimetric accuracy in real-time. Zeta's computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement, and allowing for awake and non-immobilized use in both operative and extra-operative settings.
The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

By using this website you agree to accept Medical Device News Magazine Privacy Policy